ATE403745T1 - Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis - Google Patents

Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis

Info

Publication number
ATE403745T1
ATE403745T1 AT99972008T AT99972008T ATE403745T1 AT E403745 T1 ATE403745 T1 AT E403745T1 AT 99972008 T AT99972008 T AT 99972008T AT 99972008 T AT99972008 T AT 99972008T AT E403745 T1 ATE403745 T1 AT E403745T1
Authority
AT
Austria
Prior art keywords
sepsis
drugs
development
determining susceptibility
treating
Prior art date
Application number
AT99972008T
Other languages
English (en)
Inventor
Giovine Francesco Di
Gordon Duff
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Application granted granted Critical
Publication of ATE403745T1 publication Critical patent/ATE403745T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99972008T 1998-10-30 1999-11-01 Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis ATE403745T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/183,850 US6251598B1 (en) 1998-10-30 1998-10-30 Methods for diagnosing sepsis

Publications (1)

Publication Number Publication Date
ATE403745T1 true ATE403745T1 (de) 2008-08-15

Family

ID=22674558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972008T ATE403745T1 (de) 1998-10-30 1999-11-01 Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis

Country Status (10)

Country Link
US (2) US6251598B1 (de)
EP (1) EP1127168B1 (de)
JP (1) JP2002533096A (de)
AT (1) ATE403745T1 (de)
AU (1) AU779772B2 (de)
CA (1) CA2346960A1 (de)
DE (1) DE69939269D1 (de)
ES (1) ES2308861T3 (de)
IL (1) IL142438A0 (de)
WO (1) WO2000037679A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
WO2002024951A1 (en) * 2000-09-20 2002-03-28 Genaissance Pharmaceuticals, Inc. Haplotypes of the il1b gene
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
KR20050034584A (ko) * 2001-10-05 2005-04-14 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
AU2002359431A1 (en) * 2001-11-19 2003-06-10 Interleukin Genetics, Inc. Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
CA2505843A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
TW200418992A (en) * 2002-11-12 2004-10-01 Becton Dickinson Co Diagnosis of sepsis or sirs using biomarker profiles
MXPA05005031A (es) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
WO2005038427A2 (en) * 2003-06-05 2005-04-28 Medical Gene Center Ltd. Rapid identification of viruses of the upper respiratory tract infection including sars causing coronus viruses
CA2540760C (en) * 2003-10-06 2013-01-08 Novartis Ag Use of genetic polymorphisms to predict drug-induced hepatotoxicity
US20090176206A1 (en) * 2004-03-04 2009-07-09 James Russell Toll-like receptor 2 (tlr-2) haplotypes predict outcome of patients
EP1725574A4 (de) * 2004-03-04 2008-10-29 Univ British Columbia Thrombomodulin- (thbd-) haplotypen als ergebnisindikatoren für patienten
US8034553B2 (en) * 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
RU2286154C2 (ru) * 2005-02-17 2006-10-27 Владимир Алексеевич Шатров Способ лечения воспалительных заболеваний головного мозга
WO2006106868A1 (ja) 2005-03-30 2006-10-12 Shimadzu Corporation 反応容器における不揮発性液体分注方法及び反応容器処理装置
EP1869463A4 (de) 2005-04-15 2010-05-05 Becton Dickinson Co Sepsisdiagnose
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
US20120087870A1 (en) * 2008-12-19 2012-04-12 Hentges Francois Novel caviidae allergens and uses thereof
US9913880B2 (en) 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
US10126305B2 (en) * 2013-06-25 2018-11-13 University of Pittsburg—Of the Commonwealth System of Higher Education Proteomic biomarkers of sepsis in elderly patients
EP3402900A1 (de) 2016-01-12 2018-11-21 Interleukin Genetics, Inc. Verfahren zur vorhersage der reaktion auf eine therapie
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
WO2020245402A1 (en) 2019-06-06 2020-12-10 Cardioforecast Ltd Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
EP0534978B1 (de) 1990-05-01 1999-03-24 Chiron Corporation Interleukin-i antagonist und seine verwendung
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
DE4408890A1 (de) 1994-03-16 1995-09-21 Knoll Ag Verwendung von Il-1-Antagonisten als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5942390A (en) * 1996-01-12 1999-08-24 Cedars-Sinai Medical Center Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
WO1997034616A1 (en) 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
GB9621129D0 (en) 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
GB9711040D0 (en) 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
TR200001263T2 (tr) 1997-11-07 2000-12-21 Interleukin Genetics, Inc. Kronik tıkayıcı solunum-yolu hastalığının teşhis ve terapötikleri
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis

Also Published As

Publication number Publication date
EP1127168A2 (de) 2001-08-29
WO2000037679A2 (en) 2000-06-29
JP2002533096A (ja) 2002-10-08
EP1127168B1 (de) 2008-08-06
AU779772B2 (en) 2005-02-10
US20010034032A1 (en) 2001-10-25
WO2000037679A3 (en) 2001-01-11
CA2346960A1 (en) 2000-06-29
ES2308861T3 (es) 2008-12-01
US6251598B1 (en) 2001-06-26
US6551785B2 (en) 2003-04-22
IL142438A0 (en) 2002-03-10
DE69939269D1 (de) 2008-09-18
AU3995600A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
ATE403745T1 (de) Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
DE69735295D1 (de) Verfahren zur Aufkonzentrierung von Antikörperlösungen
ATE408936T1 (de) Gerät und verfahren zur bestimmung der quelle eines lokalsignals
ATE188778T1 (de) Verfahren und verbindungen zur magnetorelaxometrischen detektion von analyten und deren verwendung
DE69430231D1 (de) Biosensor zum Messen der Alkoholkonzentration, Verfahren zur Herstellung des Biosensors, und den Biosensor benutzendes Betrunkenheitsmessgerät
DE59601159D1 (de) Verfahren zum gegenseitigen ausrichten von körpern und lagemesssonde hierfür
DE69737258D1 (de) Verfahren und Vorrichtung zur Detektion von akutem myokardischem Infarkt
DE69534399D1 (de) Verfahren und Gerät zur Bestimmung von Merkmalpunkten
DE69625777D1 (de) Verfahren zur Bestimmung der Konzentration eines magnetischen Pulvers und Vorrichtung dazu
DD138921A5 (de) Verfahren und reagens zur bestimmung von alpha-amyl&se
DE69619611D1 (de) Verfahren und Vorrichtung zur Bestimmung der petrologischen Eigenschaften von Schichtgesteinen
DE69936553D1 (de) Verfahren zur Konzentrationsmessung von NOx
DE69722172D1 (de) System und Verfahren zum Detektieren des Niveaus von Toner
DE69124511D1 (de) Verfahren für den nachweis und/oder die bestimmung von hormonen
DE69524919D1 (de) Verfahren und Vorrichtung zur Bestimmung der Konzentration von Gaskomponenten
EP0871808A4 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
ATA924378A (de) Verfahren zur bestimmung von prothrombin und reagens zur durchfuehrung des verfahrens
DE69612564D1 (de) Verfahren zur thermischen behandlung von nicht-gasförmigem material
ATE371453T1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE69934789D1 (de) Verfahren zur bestimmung der antibiotikasensitivität von bakterien
DE59814359D1 (de) Mikrostrukturierter biosensor, verwendung des biosensors und verfahren zur immobilisierung von biokatalysatoren
DE69906890T2 (de) Verfahren und vorrichtung für eine hierarchische kodierung von bildern
ATE506075T1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE69422890D1 (de) Verfahren und Vorrichtung zur Bestimmung der Konzentration von Verunreinigungselementen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties